Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

Forbes

20 Years Of Priority Review Vouchers, A Tool For Spurring Needed Drugs

20 Years Of Priority Review Vouchers, A Tool For Spurring Needed Drugs
ShareXFacebook

If the FDA approves a drug for a neglected tropical disease, the company gets a voucher that accelerates review of another drug. This remains controversial.

F

Source

Forbes

Read full article at Forbes

Opens original article in a new tab

Advertisement

Related Economy Stories

Why Private Credit Is Not a Financial Crisis Threat
Bloomberg Markets

Why Private Credit Is Not a Financial Crisis Threat

Bloomberg Senior Writer for Ideas & Culture Felix Salmon discusses with David Gura and Christina Ruffini on Bloomberg This Weekend the growing attention on private credit, a trillion-dollar asset class involving direct loans from investors to private equity-backed companies. (Source: Bloomberg)

Read more →
Jon Finer Criticizes Lack of Expertise in Iran Negotiations
Bloomberg Markets

Jon Finer Criticizes Lack of Expertise in Iran Negotiations

Former Principal Deputy National Security Advisor Jon Finer joins David Gura and Christina Ruffini on Bloomberg This Weekend to discuss the complexities involved in the Iran nuclear negotiations, emphasizing the need for a team with deep technical and legal expertise to properly assess Iranian demands and potential concessions. (Source: Bloomberg)

Read more →
Achieving a Comfortable Retirement Amid Rising Costs
Bloomberg Markets

Achieving a Comfortable Retirement Amid Rising Costs

Bloomberg Personal Finance Reporter Suzanne Woolley discusses the challenges of retiring comfortably in the face of increasing living expenses. She emphasizes to Bloomberg This Weekend hosts David Gura and Christina Ruffini that there is no universal dollar amount for retirement savings, as the required sum depends heavily on individual lifestyle choices and location. (Source: Bloomberg)

Read more →
Advertisement